BioCamp webinar on career opportunities in the pharmaceutical industry

  • This year’s 10th BioCamp, for which a record number of 191 students from 24 study countries applied, was postponed due to the Covid-19 pandemic. It will take place from October 18 – 20, 2020, if the situation will allow it. 
  • To bridge the time until the event, Novartis in Slovenia organised in May a webinar on career opportunities in the pharmaceutical industry which was attended by more than 100 students from more than 10 countries. 
  • The BioCamp is one of the HR practices, with which Novartis in Slovenia addresses young talents and presents them the world of the international pharmaceutical industry and career opportunities. 
26. 5. 2020

At this time, Novartis in Slovenia normally hosted the BioCamp, a three-day forum that brings together top students of undergraduate and postgraduate programs in natural and economic sciences and technology. This year’s jubilee 10th edition of BioCamp, for which a record number of 191 students from 24 study countries applied, was due to the Covid-19 pandemic postponed to October. Nevertheless, in May, all the applicants were invited to attend a webinar where they learnt about career opportunities in the pharmaceutical industry. 

»The BioCamp has been continuously evolving over ten years. We invite young talents, therefore, we have to be constantly up to date with current developments, mindset and the needs of these young experts. We have introduced quite a few novelties in this year’s 10th BioCamp and all of us at Novartis in Slovenia who are involved in the organizing, have been already looking forward to the event so it is really a pity that we had to reschedule it due to the Covid-19 pandemic. However, this challenge has brought us also a new opportunity, namely to connect in a different way with everybody who applied to attend the BioCamp and not only those who were selected to participate at the event. We are pleased to see that more than 100 students from more than 10 countries attended the webinar presenting career opportunities in the pharmaceutical industry,« said Janko Ignjatović, PhD, project manager at the Development Center Slovenia and the Chair of the BioCamp Organizing Committee. 

On the webinar, Janko Ignjatović, PhD, Nika Anžiček, PhD, Žiga Perko, Ognen Jakasanovski, Rok Hribšek, Klavdija Glavač, Nejc Klemenc, Meti Buh Gašparič PhD, and Jan Breznikar presented their own career paths at Novartis, one of the leading pharmaceutical companies in the world. In the past years, all of them participated at the BioCamp as students and today they work in different areas within Novartis in Slovenia.

»As a pharmaceutical company where knowledge and innovation are the drivers of success, we need top class associates across the wide area of our operations so we are constantly thinking about how to address and attract young talents. The BioCamp is one of the HR practices, in addition to the career breakfast and other events and activities that we plan and implement at Novartis in Slovenia with the aim of connecting with the best. Through such meetings, we can get to know better the needs of prospective associates while at the same time we can present them in more detail the opportunities for career development that we offer. As the most reputable employer in Slovenia, we will continue to develop excellent employment opportunities for experts of different profiles,« said Darja Ferčej Temeljotov, PhD, Head of Strategic Programs at Lek and until this year Chair of the BioCamp Organizing Committee.

This year’s 10th BioCamp is expected to take place October 18 to 20, 2020 in Ljubljana, the theme of the event will be new business models in the pharmaceutical industry. 

* * *

Novartis is the leading provider of medicines in Slovenia, where Lek, Novartis Pharma Services and Sandoz, operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Technical Operations, Global Drug Development, Novartis Business Services, and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Over the last eight years, the company has created more than 2,700 jobs, making us one of the biggest employers in Slovenia. Novartis invested in Slovenia more than EUR 2.5 billion since 2003. 

About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz is headquartered in Holzkirchen, in Germany’s Greater Munich area.

Sandoz is on Twitter. Sign up to follow @SandozGlobal at

About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 109,000 people of more than 145 nationalities work at Novartis around the world. Find out more at 

* * *

This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.

- end -

For additional information contact:
Katarina Klemenc
Corporate Communications 
Lek Pharmaceuticals d. d.
Phone: +386 1 580 22 43
Fax: +386 1 580 24 32